Compare Novo Nordisk A/S (NVO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sprott Uranium Miners ETF — how do they compare? Novo Nordisk A/S trades at $45.01 (market cap $198.57B), while Sprott Uranium Miners ETF trades at $56.2. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals.
| NVO | URNM | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $83.99 |
52-Week Low | $35.29 | $47.13 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
URNM, a uranium-focused ETF, trades at $57.38, up 0.54% today, with neutral technical signals and bearish moving averages. Key support lies at $55, resistance at $58. The fund provides concentrated exposure to uranium miners, benefiting from long-term supply deficits and rising AI-driven power demand, though financial ratios are not disclosed for the ETF structure.
Outlook is cautiously optimistic due to nuclear energy's role in AI infrastructure and government funding, but risks include uranium price volatility and miner concentration. Analyst sentiment is mixed, with some bullish on supply crunches while others warn of overvaluation in miner equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
